Clinical research - Press Releases

Date	Title	Company
22-Sep-2022	Kancera reports convincing preclinical results and decision to initiate clinical development of KAND567 in ovarian cancer	Kancera
22-Sep-2022	Almirall announces the initiation of a Phase I study of anti-IL-1RAP first-in-class monoclonal antibody for autoimmune dermatological diseases	Almirall
22-Sep-2022	SMART and NTU Singapore develop a quick test kit to determine a person’s immunity against COVID-19 and its variants	Blue Totem Communications
21-Sep-2022	Tower to bring the temperature of pharmaceutical logistics to CPhI	Tower Cold Chain
20-Sep-2022	Rapid growth puts Australian CRO Accelagen on the map for clinical research globally	Accelagen
11-Sep-2022	Blood Clot Retrieval Devices Market Size Will Achieve USD 5.6 Billion By 2030 Growing At 18.4% CAGR - Exclusive Report by Acumen Research and Consulting	Acumen Research And Consulting
07-Sep-2022	ABBOTT ANNOUNCES EUROPEAN LAUNCH OF AMPLATZER™ TALISMAN™ SYSTEM TO CLOSE HOLE IN HEART FOR PEOPLE AT RISK OF RECURRENT STROKE	Abbott
07-Sep-2022	KITE’S CAR T-CELL THERAPY TECARTUS® (BREXUCABTAGENE AUTOLEUCEL) GRANTED EUROPEAN MARKETING AUTHORISATION FOR THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (r/r ALL)	KITES
07-Sep-2022	Velocity Clinical Research growth skyrockets with eight site acquisitions	Velocity Clinical Research
07-Sep-2022	HTC VIVE Introduces VIVE Focus 3 Facial Tracker and Eye Tracker	HTC VIVE
07-Sep-2022	KITE’S CAR T-CELL THERAPY TECARTUS® (BREXUCABTAGENE AUTOLEUCEL) GRANTED EUROPEAN MARKETING AUTHORISATION FOR THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (r/r ALL)	KITE’S
07-Sep-2022	BRAIN TUMOR: ANTI EPILEPTIC DRUG PROMISING & TOLERABLE	St. Pölten/Krems
07-Sep-2022	Radiology technology start-up Hexarad raises further £2.2m to complete Series A funding	Radiology technology
07-Sep-2022	Almac Sciences and UCD strengthen collaboration with prestigious SFI grant	Almac Sciences
07-Sep-2022	Press Release Media Contacts: IB Communications Tel +44 (0)20 89434685 immutep@ibcomms.agency Immutep announces investigator-initiated Phase II trial evaluating LAG-3 candidate eftilagimod alpha (efti) in soft tissue sarcoma	Immutep
07-Sep-2022	Dizlin Pharmaceuticals publishes data from pharmacokinetic study (PK) (IPO-001) with Infudopa SubC (DIZ102) and Infudopa IntraV (DIZ101) in Neurology	Dizlin Pharmaceuticals AB
07-Sep-2022	LYNPARZA (olaparib) APPROVED IN GREAT BRITAIN AS ADJUVANT TREATMENT FOR PATIENTS WITH GERMLINE BRCA-MUTATED HER2-NEGATIVE HIGH-RISK EARLY BREAST CANCER	AstraZeneca
07-Sep-2022	Brainomix and Bridge Biotherapeutics, Inc. Announce Partnership to Utilize Brainomix’ AI-Powered e-ILD Software for Automated Assessment of Idiopathic Pulmonary Fibrosis (IPF)	Brainomix and Bridge Biotherapeutics
07-Sep-2022	Brainomix and Bridge Biotherapeutics, Inc. Announce Partnership to Utilize Brainomix’ AI-Powered e-ILD Software for Automated Assessment of Idiopathic Pulmonary Fibrosis (IPF)	Brainomix and Bridge Biotherapeutics, Inc.
07-Sep-2022	Aqilion has completed a rights issue	AQILION AB